Literature DB >> 21733406

An overview of tuberculosis chemotherapy - a literature review.

Susmita Sarkar1, Mavanur R Suresh.   

Abstract

Tuberculosis (TB) is a major threat in global public health. The emergence of HIV and also multi drug resistant (MDR) and extremely drug resistant (XDR)-TB poses a vital challenge to the control of the disease. For the last 40 years, no new anti-TB drug has been discovered. This literature review provides a brief discussion of existing drugs and emerging drug targets, and also of the advantages of incorporating modern drug delivery systems and immune modulators in order to improve the existing treatment regimen in terms of better efficacy, reduced drug administration frequency, shortened period of treatment and reduced drug related toxicity. The investigation for new a drug target is essential in carrying on the fight against MDR and XDR-TB. However, owing to the enormous cost and time involved in new drug development, improvement of the existing treatment regimen is seen to be a valid alternative.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733406     DOI: 10.18433/j33591

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  8 in total

Review 1.  Factors that influence current tuberculosis epidemiology.

Authors:  Juan-Pablo Millet; Antonio Moreno; Laia Fina; Lucía del Baño; Angels Orcau; Patricia García de Olalla; Joan A Caylà
Journal:  Eur Spine J       Date:  2012-05-08       Impact factor: 3.134

2.  Screening essential genes of Mycobacterium tuberculosis with the pathway enrichment method.

Authors:  Guangyu Xu; Zhaohui Ni; Yue Shi; Xiaoyu Sun; Huaidong Wang; Chengguo Wei; Guoqing Wang; Fan Li
Journal:  Mol Biol Rep       Date:  2014-08-07       Impact factor: 2.316

3.  A bispecific antibody based assay shows potential for detecting tuberculosis in resource constrained laboratory settings.

Authors:  Susmita Sarkar; Xinli L Tang; Dipankar Das; John S Spencer; Todd L Lowary; Mavanur R Suresh
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

Review 4.  Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.

Authors:  Akhand Pratap Singh; Arpan Biswas; Aparna Shukla; Pralay Maiti
Journal:  Signal Transduct Target Ther       Date:  2019-08-30

5.  Piperidinols that show anti-tubercular activity as inhibitors of arylamine N-acetyltransferase: an essential enzyme for mycobacterial survival inside macrophages.

Authors:  Areej Abuhammad; Elizabeth Fullam; Edward D Lowe; David Staunton; Akane Kawamura; Isaac M Westwood; Sanjib Bhakta; Alun Christopher Garner; David L Wilson; Peter T Seden; Stephen G Davies; Angela J Russell; Elspeth F Garman; Edith Sim
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

6.  Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study.

Authors:  Ning-Kui Niu; Juan-Juan Yin; Yin-Xue Yang; Zi-Li Wang; Zhi-Wei Zhou; Zhi-Xu He; Xiao-Wu Chen; Xueji Zhang; Wei Duan; Tianxin Yang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-08-07       Impact factor: 4.162

7.  Exploration of piperidinols as potential antitubercular agents.

Authors:  Areej Abuhammad; Elizabeth Fullam; Sanjib Bhakta; Angela J Russell; Garrett M Morris; Paul W Finn; Edith Sim
Journal:  Molecules       Date:  2014-10-10       Impact factor: 4.411

8.  Targeting the Serine Pathway: A Promising Approach against Tuberculosis?

Authors:  Marie Haufroid; Johan Wouters
Journal:  Pharmaceuticals (Basel)       Date:  2019-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.